US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% SPCX $147.49 ▲+0.00% TSLA $372.22 ▲+0.00% NVDA $210.96 ▲+0.00% NU $15.16 ▲+0.00% SNDK $1,238.03 ▲+0.00% MELI $1,810.15 ▲+0.00%
FinancialContent

Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

25.93 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rapport Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns ↗
These under-the-radar healthcare stocks are on a high growth trajectory and represent companies that recently went public. 
Via InvestorPlace
News headline image
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Preclinical data on TARPγ8 targeted compound, an analog to Rapport’s lead product candidate RAP-219, demonstrated analgesic activity in multiple pain models 
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rapport Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >